Best practice & research. Clinical haematology, 2020-03, Vol.33 (1), p.101144-101144, Article 101144
2020
Details
- Autor(en) / Beteiligte
- Titel
- Second malignancies in multiple myeloma; emerging patterns and future directions
- Ist Teil von
- Best practice & research. Clinical haematology, 2020-03, Vol.33 (1), p.101144-101144, Article 101144
- Ort / Verlag
- Netherlands: Elsevier Ltd
- Erscheinungsjahr
- 2020
- Link zum Volltext
- Quelle
- MEDLINE
- Beschreibungen/Notizen
- The changing landscape of treatment options for multiple myeloma has led to a higher proportion of patients achieving deep, long-lasting responses to therapy. With the associated improvement in overall survival, the development of subsequent second malignancies has become of increased significance. The risk of second malignancy after multiple myeloma is affected by a combination of patient-, disease- and therapy-related risk factors. This review discusses recent data refining our knowledge of these contributing factors, including current treatment modalities which increase risk (i.e. high-dose melphalan with autologous stem cell transplant and lenalidomide maintenance therapy). We highlight emerging data towards individualized risk- and response-adapted treatment strategies and discuss key areas requiring future research.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 1521-6926eISSN: 1532-1924DOI: 10.1016/j.beha.2020.101144Titel-ID: cdi_swepub_primary_oai_lup_lub_lu_se_5928a87a_a070_4db4_bcc3_1fc6e85d3602
- Format
- –
- Schlagworte
- Antineoplastic Combined Chemotherapy Protocols - therapeutic use, Autologous, Bortezomib - therapeutic use, Clinical Medicine, Clinical Trials as Topic, Disease-Free Survival, Drug Administration Schedule, Hematologi, Hematology, Hematopoietic Stem Cell Transplantation, Humans, Klinisk medicin, Lenalidomide, Lenalidomide - therapeutic use, Maintenance Chemotherapy - methods, Medical and Health Sciences, Medicin och hälsovetenskap, Melphalan, Melphalan - therapeutic use, Multiple myeloma, Multiple Myeloma - drug therapy, Multiple Myeloma - immunology, Multiple Myeloma - mortality, Multiple Myeloma - pathology, Neoplasm, Residual, Neoplasms, Neoplasms, Second Primary - drug therapy, Neoplasms, Second Primary - immunology, Neoplasms, Second Primary - mortality, Neoplasms, Second Primary - pathology, Risk Factors, Second primary, Thalidomide - therapeutic use, Transplantation, Transplantation, Autologous